Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation

Blood

Volumn 106, Issue 1, 2005, Pages 304-310

  Chou, Wen Chien ^b   Chen, Hsuan Yu ^c   Yu, Sung Liang ^c   Cheng, Linzhao ^c   Yang, Pan Chyr ^c   Dang, Chi V ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ARSENIC; ARSENIC TRIOXIDE; HYDROGEN PEROXIDE; MYC PROTEIN; PROTEIN C 17; REACTIVE OXYGEN METABOLITE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; ONCOGENE C MYC; OXIDATION KINETICS; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION REGULATION;

EID: 22044440559     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2005-01-0241     Document Type: Article

References (46)

1. Chou WC, Dang CV. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol. 2005;12:1-6.
2. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2:705-713.
3. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist. 2001;(suppl 2):3-10.
4. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62:3893-3903.
5. Nasr R, Rosenwald A, El-Sabban ME, et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood. 2003;101:4576-4582.
6. Li M, Cai JF, Chiu JF. Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem. 2002;87:29-38.
7. Liu L, Trimarchi JR, Navarro P, Blasco MA, Keefe DL. Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability and apoptosis. J Biol Chem. 2003;278:31998-32004.
8. Wu MM, Chiou HY, Ho IC, Chen CJ, Lee TC. Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ Health Perspect. 2003; 111:1429-1438.
9. Rea MA, Gregg JP, Qin Q, Phillips MA, Rice RH. Global alteration of gene expression in human keratinocytes by inorganic arsenic. Carcinogenesis. 2003;24:747-756.
10. Schwerdtle T, Walter I, Mackiw I, Hartwig A. Induction of oxidative DNA damage by arsenite and its trivalent and pentavalent methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis. 2003;24:967-974.
11. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102-2111.
12. Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA. 2004;101:4578-4583.
13. Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest. 2001;108:1541-1547.
14. 3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
15. Kim J, Yoon HW, Kwon KS, Lee SR, Rhee SG. Identification of proteins containing cysteine residues that are sensitive to oxidation by hydrogen peroxide at neutral pH. Anal Biochem. 2000;283: 214-221.
16. Korn SH, Wouters EF, Vos N, Janssen-Heininger YM. Cytokine-induced activation of nuclear factor-kappa B is inhibited by hydrogen peroxide through oxidative inactivation of IκB kinase. J Biol Chem. 2001;276:35693-35700.
17. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol. 2003;4: R70.
18. Babior BM. NADPH oxidase: an update. Blood. 1999;93:1464-1476.
19. Doussiere J, Bouzidi F, Vignais PV. The S100A8/A9 protein as a partner for the cytosolic factors of NADPH oxidase activation in neutrophils. Eur J Biochem. 2002;269:3246-3255.
20. Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature. 1990;343:278-281.
21. Dixon RA, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase- activating protein for leukotriene synthesis. Nature. 1990;343:282-284.
22. Matsumoto R, Hirashima M, Kita H, Gleich GJ. Biological activities of ecalectin: a novel eosinophil-activating factor. J Immunol. 2002;168: 1961-1967.
23. Henderson JP, Byun J, Williams MV, et al. Bromination of deoxycytidine by eosinophil peroxidase: a mechanism for mutagenesis by oxidative damage of nucleotide precursors. Proc Natl Acad Sci U S A. 2001;98:1631-1636.
24. van Dalen CJ, Kettle AJ. Substrates and products of eosinophil peroxidase. Biochem J. 2001;358: 233-239.
25. Brennan M. A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive oxygen species. J Biol Chem. 2001;276:17415-17427.
26. Bokarewa MI, Jin T, Tarkowski A. Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J Rheumatol. 2003;30:1719-1724.
27. Welling MM, Hiemstra PS, van den Barselaar MT, et al. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J Clin Invest. 1998;102:1583-1590.
28. Golightly LM, Thomas LL, Dvorak AM, Ackerman SJ. Charcot-Leyden crystal protein in the degranulation and recovery of activated basophils. J Leukoc Biol. 1992;51:386-392.
29. Ben-Baruch A, Bengali KM, Biragyn A, et al. Interleukin-8 receptor beta: the role of the carboxyl terminus in signal transduction. J Biol Chem. 1995;270:9121-9128.
30. Liu X, Rapp N, Deans R, Cheng L. Molecular cloning and chromosomal mapping of a candidate cytokine gene selectively expressed in human CD34+ cells. Genomics. 2000;65:283-292.
31. Ramon O, Wong HK, Joyeux M, et al. 2'-Deoxyguanosine oxidation is associated with decrease in the DNA-binding activity of the transcription factor Sp1 in liver and kidney from diabetic and insulin-resistant rats. Free Radic Biol Med. 2001;30:107-118.
32. Webster KA, Prentice H, Bishopric NH. Oxidation of zinc finger transcription factors: physiological consequences. Antioxid Redox Signal. 2001;3: 535-548.
33. Jackson SP, Tjian R. O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell. 1988;55: 125-133.
34. Ye X, Liu SF. Lipopolysaccharide down-regulates Sp1 binding activity by promoting Sp1 protein dephosphorylation and degradation. J Biol Chem. 2002;277:31863-31870.
35. Marnett LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest. 2003;111:583-593.
36. Gombart AF, Shiohara M, Kwok SH, Agematsu K, Komiyama A, Koeffler HP. Neutrophil-specific granule deficiency: homozygous recessive inheritance of a frameshift mutation in the gene encoding transcription factor CCAAT/enhancer binding protein-epsilon. Blood. 2001;97:2561-2567.
37. Royer-Pokora B, Kunkel LM, Monaco AP, et al. Cloning the gene for an inherited human disorder-chronic granulomatous disease-on the basis of its chromosomal location. Nature. 1986; 322:32-38.
38. Dinauer MC, Orkin SH. Chronic granulomatous disease. Annu Rev Med. 1992;43:117-124.
39. Holmes A, Abraham DJ, Chen Y, et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem. 2003;278:41728-41733.
40. Watkin R, Nawrot, T, Potts RJ, Hart BA. Mechanisms regulating the cadmium-mediated suppression of Sp1 transcription factor activity in alveolar epithelial cells. Toxicology. 2003;184:157-178.
41. Denu JM, Tanner KG. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry. 1998;37:5633-5642.
42. Barrett WC, DeGnore JP, Keng YF, Zhang ZY, Yim MB, Chock PB. Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase 1B. J Biol Chem. 1999;274:34543- 34546.
43. Dynan WS, Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell. 1983;35:79-87.
44. Dynan WS, Sazer S, Tjian R, Schimke RT. Transcription factor Sp1 recognizes a DNA sequence in the mouse dihydrofolate reductase promoter. Nature. 1986;319:246-248.
45. Shou Y, Baron S, Poncz M. An Sp1-binding silencer element is a critical negative regulator of the megakaryocyte-specific alphaIIb gene. J Biol Chem. 1998;273:5716-5726.
46. Ogra Y, Suzuki K, Gong P, Otsuka F, Koizumi S. Negative regulatory role of Sp1 in metal responsive element-mediated transcriptional activation. J Biol Chem. 2001;276:16534-16539.